Written question asked by Daisy Cooper (Liberal Democrat) on Monday, 25 April 2022, in the House of Commons. It was due for an answer on Thursday, 28 April 2022 (named day). It was answered by Maggie Throup (Conservative) on Thursday, 28 April 2022 on behalf of the Department of Health and Social Care.
Tixagevimab/cilgavimab
- Question
-
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 April 2022 to Question 151279, on Evusheld, whether the UKHSA has reviewed studies published by the US Food and Drug Administration and European Medicines Agency on the effectiveness of Evusheld against the covid-19 omicron variant; and for what reason the UKHSA has decided to undertake duplicate studies on the effectiveness of that drug.
- Answer
-
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
Secondary information
- Type
- Written question
- Reference
- 159087
- Session
- 2021-22
- Related items
- Subjects
- Testing Tixagevimab/cilgavimab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-05-24 10:00:43 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/159087
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/159087
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/159087